The new Vital Signs Measurement System from DynoSense Corp. was approved by the Food and Drug Administration on Aug. 13.
The cloud-based platform is capable of capturing and recording electrocardiogram (ECG), respiration rate (RR), oral body temperature (TEMP), functional oxygen saturation of arterial hemoglobin (SpO2), optical photoplethysmogram (PPG) for pulse rate (PR) and heart rate (HR). This allows the intelligent analytic engine to interpret changes in BP, perfusion index and cardiac problems such as Atrial Fibrillation (AFib) and Heart Rate Variability (HRV).
"I am very proud of our technological accomplishments and proven capabilities to date," said Saeed Azimi, founder and CEO of DynoSense Corp. "We are on the path to take advantage of the shift to advanced AI based monitoring systems and Digital Therapeutics methods to improve health and wellness. As a person with my own chronic health condition, I have come to understand the power of receiving informed preventive and self-empowering alerts that are coupled with my clinical care specialists."
DynoSense’s market includes elderly health care, chronic care, hospital discharge management, geographically isolated regions, contract research organizations and consumer health and wellness.
